Melanoma research gets a funding boost from NHMRC
9 December 2016
Research projects led by Melanoma Institute Australia (MIA) have been awarded almost $6 million in the latest National Health and Medical Research Council (NHMRC) funding round which will enable vital progression of research into melanoma prevention and treatment. Projects led by MIA researchers have been awarded the highly competitive funding:
- Professor Georgina Long (MIA and The University of Sydney) received a Practitioner Fellowship (5 years) to investigate the underlying biology of patients’ responses to treatment. By understanding why some patients respond well to therapies when others develop resistance will help us develop tests to ensure the best possible treatment is given to each individual patient. In addition, it will also help identify the ideal drug therapy combinations to improve patient outcomes further or prevent metastatic melanoma altogether.
- Professor Nicholas Hayward (MIA and QIMR Berghofer) received a Research Fellowship (3 years) to investigate genetic predisposition to melanoma in the general population and predisposed families, and the genes involved in traits underlying melanoma development. He was also awarded a Project Grant (5 years) to conduct a comprehensive genetic analysis of acral melanoma to ultimately identify new drug targets to treat this disease. Although an uncommon subtype of melanoma, acral melanoma has a bad prognosis and has been poorly characterised at the molecular level.
- Professor Helen Rizos (MIA and Macquarie University) received two Project Grants to investigate the cell biology of melanoma. These project grants involved a team of chief investigators from MIA, who have collaborated on melanoma response and resistance for many years, including Professor Richard Kefford, Professor Georgina Long, Dr Matteo Carlino, Dr Alexander Menzies and Dr Xu Dong Zhang, and new collaborator Professor Barbara Fazekas de St Groth. The first Project Grant (4 years) will be used to investigate the mechanisms of response and resistance to combination immunotherapies in order to enhance the duration and rate of patient response. The second Project Grant (4 years) will use tumour samples of patients who have developed resistance to immunotherapies to determine the underlying mechanisms involved. This information will accelerate the identification of new combination therapies to improve patient outcomes.
- Associate Professor Anne Cust (MIA and The University of Sydney) was awarded a 4-year Project Grant to improve skin cancer prevention. Her research will evaluate whether they can improve skin cancer prevention behaviours by giving personalised information about melanoma genetic risk. They will also explore the psycho-social, ethical and economic implications of receiving this information, with the ultimate aim to positively influence the future of skin cancer prevention in Australia.
To date, the 2016 NHMRC Grant Application Round has resulted in the commitment of more than $703 million to fund health and medical research across Australia.
Australia unites taking small steps to make a big difference for melanoma research
Thank you to everyone involved in making Melanoma March 2016 a huge success
And they're off... Melanoma March 2016 begins!
Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.
5 Minutes with Carole Renouf
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.
Opinion: Outing Melanoma
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.
Congratulations Professor Georgina Long
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.
Melanoma March 2016: Where your funds are going
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.
New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.
Melanoma March 2016 is launched
Melanoma March was officially launched today with the announcement of the national research project funded by the march.
MIA's research pivotal in TGA's approval of new therapy
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.
The Face of Melanoma March
Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.
Q&A With An Expert: Dermatologist
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.
New figures show melanoma most common cancer in young Queenslanders
Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.
5 minutes with Associate Professor Georgina Long
As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.
Watch Your Mate's Back: helping young Australians recognise melanoma
MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same.
Your Guide to Early Melanoma patient information packs
Your Guide to Early Melanoma is a new patient information pack to offer additional information for those affected by melanoma.
Clinicians invited to MIA's 'World Round Up' event
Special Event to share advances in diagnosis and treatment of both early and late stage melanoma
Melanoma landmark study to help further develop personalised cancer treatment
MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma
Sunrise features inspiring story of MIA patient
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.
Leading researchers honoured for global contribution to science and innovation
Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.
MIA welcomes ground-breaking new PBS melanoma treatment
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).